Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.52 |
| ▸ | MAG | P20916 | 6/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SELE | P16581 | 2/20 | 0.39 |
| ▸ | SELL | P14151 | 1/20 | 0.38 |
| ▸ | SELP | P16109 | 1/20 | 0.38 |
| ▸ | CD22 | P20273 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18934784 | 0.86 | MAG (0.47) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL14819216 | 0.86 | MAG (0.47) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL17897325 | 0.86 | SIGLEC7 (0.66) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL17889795 | 0.86 | SIGLEC7 (0.66) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL16377870 | 0.82 | SIGLEC7 (0.66) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL20193276 | 0.82 | SIGLEC7 (0.66) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL12223144 | 0.81 | SIGLEC7 (0.73) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL15706045 | 0.81 | SIGLEC7 (0.73) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL12223230 | 0.81 | SIGLEC7 (0.73) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL17897142 | 0.80 | SIGLEC7 (0.59) | SIGLEC7MAGMAPK1SELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216510-A1 | CHIMERIC ANTIGEN RECEPTORS TO SIALYL-TN GLYCAN ANTIGEN | UNIV RAMOT (IL) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216510-A1 | CHIMERIC ANTIGEN RECEPTORS TO SIALYL-TN GLYCAN ANTIGEN | SIGLEC7, CD47, SIGLEC9 | SIGLEC7 1/4885MAG 337/4885MAPK1 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.